Navigation Links
Avastin effective at delaying brain tumor progression in recurrent disease
Date:4/6/2009

(SEATTLE) The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.

The patients all had a recurrent malignant glioma known as alkylator-refractory anaplastic oligodendroglioma (AO), for which there is no existing standard therapy. Oligodendrogliomas begin in brain cells called oligodendrocytes, which provide support around nerves by building a sheath of myelin and facilitating electrical nerve impulses. The relatively uncommon tumor affects about 2,000 persons annually in the U.S. Most are under age 50.

Avastin, known generically as bevacizumab, is the first approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. It is approved so far to treat certain metastatic colon cancers and non-small cell lung cancer.

"Bevacizumab is an important drug for us," said Marc Chamberlain, M.D., author of the study published in the April 15 edition of the journal Cancer. "Of all of the targeted therapies for gliomas, this has been the most promising. And this is practice changing."

Therapy for treating recurrent high-grade gliomas is palliative. All patients with these high-grade tumors eventually die of their cancer. However, bevacizumab has the potential to be the best palliative treatment, according to Chamberlain, who is director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University of Washington School of Medicine.

Chamberlain said he expects that patients treated with the drug will have a marked improvement in their quality of life because the use of steroids, a common treatment that has significant side effects, can be greatly reduced or even eliminated.

"While treatment with Avastin does dramatica
'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Panel Says No to Avastin for Advanced Breast Cancer
2. Taxol with avastin produces noteworthy results
3. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
6. FDA OKs Avastin for Advanced Breast Cancer
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
10. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
11. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter TUESDAY, ... such as Adderall, Ritalin and Concerta -- used to ... growth, a new study suggests. "Stimulant medication did ... researcher Dr. Slavica Katusic, an associate professor of pediatrics ... noted that results of earlier studies have been mixed, ...
(Date:9/2/2014)... (HealthDay News) -- Drinking and marijuana may lead to ... study suggests. Researchers analyzed 2007 to 2011 data ... who said they had used alcohol or marijuana at ... was associated with more unsafe driving, damage to relationships ... while under the influence of alcohol, especially among females. ...
(Date:9/2/2014)... ALEXANDRIA, VAThe latest research on sleep apnea, tonsillectomies, ... otolaryngic topics will be presented in Orlando, FL, ... OTO EXPO℠ of the American Academy of OtolaryngologyHead ... meeting of ear, nose, throat, head and neck ... research to be presented were released today, and ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated compression ... a luxurious line of graduated compression socks with natural fibers. ... Socks are joining the SIGVARIS MEDICAL collection for those who ... of natural cotton fibers. , “When people step into ... socks as soft as the finest cashmere,” says Clay Walker, ...
(Date:9/2/2014)... September 02, 2014 The exclusive ClinicCRM ... was designed to help doctors manage foreign patient flow, ... patient conversion rates and clink revenue. Since its launch ... increase in sales revenue and a 70 percent increase ... in their own healthcare practices. , With its ease ...
Breaking Medicine News(10 mins):Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4
... ... ... ... ...
... ... ... ... ...
... CREST trial that compared traditional surgery with less-invasive stenting ... is being called "seminal and robust." The Carotid ... safety and efficacy of both procedures are roughly equal. ... is one of the largest randomized stroke prevention trials ...
... , ... California Dental Hygienists’ Association Conducts Statewide Outreach Efforts to Provide Low-Income Children Access ... ... National Children’s Dental Health Month draws to a close, California’s dental hygienists ...
... ago, researchers say, , FRIDAY, Feb. 26 (HealthDay News) -- ... than 12,000 years ago, new research suggests. , The researchers ... a major determinant of small size in dogs. The gene ... the Middle Eastern gray wolf, according to the study, published ...
... newcomers hold mettle against warfarin, aspirin , FRIDAY, Feb. ... that the mainstays of anti-clotting therapy, namely warfarin and ... , Researchers presenting their findings during a Friday news ... San Antonio show that one new drug, dabigatran (Pradaxa), ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
(Date:9/2/2014)... , España, September 2, 2014 ... de fibrilación atrial muestran agentes antitrombóticos no utilizados ... -- Las presentaciones de GARFIELD-AF en ... el tratamiento y los resultados de pacientes en ... diaria --    Los datos de ...
(Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
(Date:9/2/2014)... 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... of the company at the Morgan Stanley Global Healthcare Conference ... Presentation date: Tuesday September 9, 2014 , Presentation time: ... and 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Langan, Vice President of Marketing and Business Development, announced ... labeling for sterile intravenous compounded ICU Services at ... May 19-24, 2012 in Orlando, Florida. (Logo: ... care professionals to visit Booth #2668 to see how ...
...  Varian Medical Systems (NYSE: VAR ) will ... and other conditions non-invasively at the 2012 International Conference ... in San Francisco.  "We,re excited about ... not be familiar with radiosurgery as a treatment option ...
Cached Medicine Technology:PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: